Literature DB >> 29286193

Eligibility of patients for minimally invasive breast cancer therapy based on MRI analysis of tumor proximity to skin and pectoral muscle.

Laura G Merckel1, Erik Verburg1,2,3, Bas H M van der Velden1,2, Claudette E Loo4, Maurice A A J van den Bosch1, Kenneth G A Gilhuijs1,2.   

Abstract

There is growing interest in minimally invasive breast cancer therapy. Eligibility of patients is, however, dependent on several factors related to the tumor and treatment technology. The aim of this study is to assess the proportion of patients eligible for minimally invasive breast cancer therapy for different safety and treatment margins based on breast tumor location. Patients with invasive ductal cancer were selected from the MARGINS cohort. Semiautomatic segmentation of tumor, skin, and pectoral muscle was performed in Magnetic Resonance images. Shortest distances of tumors to critical organs (ie, skin and pectoral muscle) were calculated. Proportions of eligible patients were determined for different safety and treatment margins. Three-hundred-forty-eight patients with 351 tumors were included. If a 10 mm safety margin to skin and pectoral muscle is required without treatment margin, 72.3% of patients would be eligible for minimally invasive treatment. This proportion decreases to 45.9% for an additional treatment margin of 5 mm. Shortest distances between tumors and critical organs are larger in older patients and in patients with less aggressive tumor subtypes. If a 10 mm safety margin to skin and pectoral muscle is required, more than two-thirds of patients would be eligible for minimally invasive breast cancer therapy.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  breast cancer; magnetic resonance imaging; minimally invasive therapy; segmentation; tumor location

Mesh:

Year:  2017        PMID: 29286193     DOI: 10.1111/tbj.12984

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  2 in total

1.  A Breast-Specific MR Guided Focused Ultrasound Platform and Treatment Protocol: First-in-Human Technical Evaluation.

Authors:  Allison Payne; Robb Merrill; Emilee Minalga; J Rock Hadley; Henrik Odeen; Lorne W Hofstetter; Sara Johnson; Christine Tunon de Lara; Sophie Auriol; Stephanie Recco; Erik Dumont; Dennis L Parker; Jean Palussiere
Journal:  IEEE Trans Biomed Eng       Date:  2021-02-19       Impact factor: 4.538

2.  Clinical Value of Ultrasound-Guided Minimally Invasive Biopsy in the Diagnosis or Treatment of Breast Nodules.

Authors:  Yan-Hong Gao; Shi-Cong Zhu; Ya Xu; Shun-Ji Gao; Yu Zhang; Qun-An Huang; Wen-Hong Gao; Jian Zhu; Hui-Juan Xiang; Xu-Hui Gao
Journal:  Cancer Manag Res       Date:  2020-12-23       Impact factor: 3.989

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.